Deutsche Bank AG Takes $2.96 Million Position in Supernus Pharmaceuticals, Inc. $SUPN

Key Points

• Deutsche Bank acquired 63,729 shares of Supernus Pharmaceuticals in the second quarter, worth approximately $2.96 million and representing a 0.11% stake. Several other institutional investors also initiated positions.
• Supernus reported quarterly revenue of $219.1 million, up 32.4% year over year and above estimates, but posted an EPS loss of $1.01, missing consensus by $1.43.
• Analyst sentiment remains broadly positive, with an average “Moderate Buy” rating and a $62.83 price target, compared with shares recently trading at $44.88.

Deutsche Bank AG acquired a new position in Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report) in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 63,729 shares of the specialty pharmaceutical company's stock, valued at approximately $2,964,000. Deutsche Bank AG owned 0.11% of Supernus Pharmaceuticals as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Rice Hall James & Associates LLC bought a new position in Supernus Pharmaceuticals in the 2nd quarter worth approximately $22,800,000. Global Retirement Partners LLC purchased a new position in shares of Supernus Pharmaceuticals in the second quarter worth $64,000. Bank of New York Mellon Corp bought a new position in shares of Supernus Pharmaceuticals during the second quarter worth $17,553,000. State of Wyoming purchased a new position in Supernus Pharmaceuticals during the second quarter valued at $253,000. Finally, GSA Capital Partners LLP bought a new stake in Supernus Pharmaceuticals in the 2nd quarter valued at $622,000.

Supernus Pharmaceuticals Price Performance

Shares of NASDAQ SUPN opened at $44.88 on Thursday. The company has a market cap of $2.61 billion, a P/E ratio of -23.37, a PEG ratio of 0.84 and a beta of 0.56. Supernus Pharmaceuticals, Inc. has a 1 year low of $42.45 and a 1 year high of $59.68. The firm has a 50-day simple moving average of $46.83 and a two-hundred day simple moving average of $48.74.

Supernus Pharmaceuticals (NASDAQ:SUPN - Get Free Report) last released its earnings results on Monday, August 3rd. The specialty pharmaceutical company reported ($1.01) EPS for the quarter, missing analysts' consensus estimates of $0.42 by ($1.43). Supernus Pharmaceuticals had a negative net margin of 13.23% and a positive return on equity of 11.13%. The business had revenue of $219.06 million for the quarter, compared to the consensus estimate of $205.31 million. During the same period in the prior year, the company posted $0.40 EPS. The company's quarterly revenue was up 32.4% compared to the same quarter last year. As a group, equities research analysts expect that Supernus Pharmaceuticals, Inc. will post 1.97 EPS for the current year.

Analysts Set New Price Targets

Several research analysts have commented on the stock. Zacks Research raised shares of Supernus Pharmaceuticals from a "hold" rating to a "strong-buy" rating in a report on Thursday, August 6th. Cantor Fitzgerald upped their price objective on Supernus Pharmaceuticals from $63.00 to $67.00 and gave the stock an "overweight" rating in a report on Thursday, July 9th. Wall Street Zen cut shares of Supernus Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings reaffirmed a "sell (d+)" rating on shares of Supernus Pharmaceuticals in a research note on Wednesday, June 24th. One investment analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average target price of $62.83.

Supernus Pharmaceuticals Company Profile

Supernus Pharmaceuticals, Inc, headquartered in Rockville, Maryland, is a specialty pharmaceutical company dedicated to developing and commercializing central nervous system (CNS) therapies. Since its founding in 2003, Supernus has focused on advancing treatments for neurological disorders, with an emphasis on improving patient quality of life through innovative dosage forms and sustained‐release formulations.

The company's marketed portfolio includes Trokendi XR and Oxtellar XR, extended‐release antiepileptic medications designed to maintain stable drug levels for seizure control, as well as Qelbree (viloxazine extended‐release capsules), approved for the treatment of attention‐deficit/hyperactivity disorder (ADHD) in pediatric and adult patients.

Want to see what other hedge funds are holding SUPN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source